BusinessMinerva Neurosciences Reports First Quarter 2018 Financial Results and Business UpdatesBy Nasdaq OMXMay 3, 2018, 11:30 AM UTC
BusinessMinerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 2018By Nasdaq OMXApr 26, 2018, 12:30 PM UTC
BusinessMinerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive DisorderBy Nasdaq OMXApr 9, 2018, 12:30 PM UTC
BusinessMinerva Neurosciences to Host Key Opinion Leader Meeting on the Negative Symptoms of Schizophrenia on Thursday, March 22By Nasdaq OMXMar 15, 2018, 12:30 PM UTC
BusinessMinerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business UpdatesBy Nasdaq OMXMar 12, 2018, 11:30 AM UTC
BusinessMinerva Neurosciences to Report Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2018By Nasdaq OMXMar 5, 2018, 1:31 PM UTC
BusinessMinerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent DirectorBy Nasdaq OMXFeb 5, 2018, 1:30 PM UTC
BusinessMinerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With Major Depressive DisorderBy Nasdaq OMXDec 21, 2017, 1:00 PM UTC
